Medicare increases payments for oncology infusion and begins a one-year demonstration project that pays oncologists to assess the side effects of chemotherapy.
CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.
Also Unclear whether HHS Secretary Tommy Thompson will depart as previously planned.
California approves $3 billion program for stem-cell research.
Oklahoma’s new cigarette tax will provide $7 million a year to the University of Oklahoma Cancer Center.
National Cancer Policy Board will end in 2005, NCI to support a cancer forum at IOM.
Funding opportunities listed.
October issue of Business & Regulatory Report included.
Trending Stories
- The story of daraxonrasib is the ultimate hero’s journey
A narrative curve with twists, turns, intrigue, drama—and a blow to a mighty foe - As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Pancreatic cancer breakthrough came from smart scientists making smart bets—not from politicization of science
- At Senate hearing, Brown’s El-Deiry and other witnesses say they were targeted for arguing that mRNA vaccine may be linked to cancer
- Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
- Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.”
